Market research
308.F Conformis, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 226M
- P/E ratio
- 11.98
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.33
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 226M
- P/E ratio
- 11.98
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.33
About
About Conformis, Inc
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Argentina, the United Arab Emirates, the Sultanate of Oman, Italy, San Marino, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 308.F discussion.
5 years, 4 months ago
Conformis, Inc is currently in a long term uptrend where the price is trading 17.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Conformis, Inc's total revenue sank by 16.0% to $17M since the same quarter in the previous year.
Its net income has dropped by 21.9% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 17.0% to $-4M since the same quarter in the previous year.
Based on the above factors, Conformis, Inc gets an overall score of 3/5.